Mercia Technologies PLC has completed a £500,000 investment into Oxford Genetics, a synthetic biology company with significant expertise in DNA design. This investment follows the £1.0million of additional capital which was provided by Mercia in October 2016 in order to expand the company's management team, board, patent portfolio and commercialisation strategy.
Oxford Genetics joined Mercia's 'Emerging Stars' portfolio of direct investments in December 2015 having first received investment from the Group's managed funds in 2013, as one of the founding investors. The company has now received a total of £5.8million in grants and investment. Mercia currently has a direct equity stake of 47.9%. This latest investment will be used to expand Oxford Genetics' reach into the US market and further drive sales growth alongside its recent access to CRISPR technology, whilst continuing to support its promising Research and Development at its state-of-the art facilities on the Oxford Science Park.
To read the full RNS announcement, click here.